Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis

Overview

Rheumatoid arthritis is a chronic systemic disease, which is characterized by chronic inflammation in the synovial tissue. Rheumatoid arthritis ultimately results in the destruction of cartilage, bone and ligaments and joint deformity. The underlying hypothesis is that autologous bone marrow-derived mesenchymal and specific populations of stem cells has anti-inflammatory and regenerative effects and thus potentially alleviates the progression of rheumatoid arthritis. The study is to explore the safety and efficacy of BM-SC transplantation in treatment of rheumatoid arthritis.

Full Title of Study: “Transplantation of Autologous Purified Bone Marrow Derived Specific Populations of Stem Cells and Mesenchymal Stem Cells in Patients With Rheumatoid Arthritis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2021

Detailed Description

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects joints. It typically results in swollen and painful joints. Pain and stiffness often worsen after rest. Most frequently, the wrist and hands are involved, with the same joints typically involved on both sides of the body. RA affects between 0.5-1% of adults in the developed world with between 5-50 per 100,000 people newly developing the disease each year. Onset is most frequent during middle age and women are affected 2.5 times as frequently as men. The goal of treatment is to reduce pain, decrease inflammation, and improve a person's overall functioning and quality of life. Herein, the investigators study the safety and efficacy of the immunomodulatory effects of bone marrow-derived stem cells administered intravenously and the regenerative and repair potential of bone marrow-derived stem cells transplanted into the joints of patients with RA.

Interventions

  • Biological: Stem Cell Transplantation
    • Intravenous administration of autologous bone marrow derived stem cells for immunomodulation. Transplantation of autologous bone marrow derived stem cells in joints.

Arms, Groups and Cohorts

  • Experimental: Stem Cells
    • Autologous bone marrow-derived stem cell transplantation.

Clinical Trial Outcome Measures

Primary Measures

  • Evaluation of Pain Reduction measured by VAS scaling
    • Time Frame: 1 month
    • measured by VAS scaling

Secondary Measures

  • Evaluation of the Physical Activity measure by WOMAC scoring
    • Time Frame: 1 month
  • Evaluation the resurfacing of articular cartilage by MRI
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • 17-75 years old – The presence of osteoarthritis based on MRI and American Rheumatism Association criteria since 6 months before treatment. Exclusion Criteria:

  • Subjects with addition major health condition/disease diagnoses – Subjects that are pregnant or breastfeeding

Gender Eligibility: All

Minimum Age: 17 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Stem Cells Arabia
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.